A Randomized Phase II Trial of Vandetanib (ZD6474) in Combination With Carboplatin Versus Carboplatin Alone Followed by Vandetanib Alone in Adults With Recurrent High-Grade Gliomas

Model scores of the 29,894 trials active now.

Model score 20% for any early termination, 11% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 22% of the time (376 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2015-12-31. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: patients mustor equalequal toventricularmri
  Phrases that lowered it: patients whooralmmscreeningdaily
• Phase: 2 (raises risk) · Design
• Accepts healthy volunteers: No (raises risk) · Who can join
• Maximum age: 100 (lowers risk) · Who can join
• Sponsor's past termination rate: 5.6% (lowers risk) · Sponsor's track record
• Disease area, cancer: Yes (raises risk) · Disease area
• Sponsor's past trials: 322 (lowers risk) · Sponsor's track record
• Trials the sponsor started in the prior 2 years: 223 (lowers risk) · Sponsor's track record
• Drug's FAERS reports with a death: 18.0% (lowers risk) · Drug's FDA history
• Design: parallel (raises risk) · Design
• Disease area, neurology: Yes (raises risk) · Disease area
• Minimum age: 18 (raises risk) · Who can join
• Primary purpose: treatment (raises risk) · Design
• Has a data monitoring committee: No (lowers risk) · Design
• Disease area, dermatology: No (lowers risk) · Disease area
• Drug's FAERS reports marked serious: 91.0% (raises risk) · Drug's FDA history
• Collaborators: 0 (raises risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Phase I Abraxane Weekly and Three Weekly Schedule With Vandetanib NCT00667147 · started 2008 · scored riskier than 98% of active trials completed
• Ph I Dose Escalation Trial of Vandetanib in Combo w Etoposide for Malignant Gliomas NCT00613223 · started 2008 · scored riskier than 96% of active trials completed
• Tandutinib Plus Bevacizumab to Treat Recurrent Brain Tumors NCT00667394 · started 2008 · scored riskier than 24% of active trials completed
• Study of GemOx and Vandetanib in Advanced Solid Malignancy NCT00660725 · started 2009 · scored riskier than 82% of active trials completed
• A Targeted Phase I/II Trial of ZD6474 (Vandetanib; ZACTIMA) Plus the Proteasome Inhibitor, Bortezomib (Velcade ), in Adults With Solid Tumors With a Focus on Hereditary or Sporadic, Locally Advanced or Metastatic Medullary Thyroid Cancer (MTC) NCT00923247 · started 2009 · scored riskier than 61% of active trials terminated

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.